Emily Ray, MD, MPH, talks with Ian Maurer, MS, about the potential advantages and limitations of using AI in oncology and in the clinic.

Taiwo Adesoye, MD, MPH, talks with Eun-Sil Shelley Hwang, MD, about the results of the COMET study, which finds that active monitoring is a viable option for some patients with low-risk DCIS.

Lisa Anne Carey, MD, talks with Otto Metzger, MD, about the results of the phase 3 PATINA trial, which evaluated the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy after induction treatment for hormone receptor-positive (HR+)/HER-positive metastatic breast cancer.

Richard C. Zellars, MD, talks with Jean Wright, MD, about the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trial, which evaluated the impact of tamoxifen only after breast conservation surgery for “good risk” ductal carcinoma in situ.

SABCS program director Kate Lathrop, MD, talks with Komal Jhaveri, MD, FACP, about the results of phase 3 EMBER-3 trial, which evaluated the role of imlunestrant as monotherapy or in combination with abemaciclib in patients with ER+, HER2- advanced breast cancer whose disease had recurred or progressed during or after an aromatase inhibitor alone or…

SABCS program director Kate Lathrop, MD, talks with Anne Welsh, PhD—a clinical psychologist and executive coach who organizes the Navigating Success Career Development workshop for women at SABCS—about the importance of career development programs for women in STEM.

SABCS program director Kate Lathrop, MD, talks with Laura J. van ‘t Veer, PhD, director of applied genomics and leader of the Breast Oncology Program for the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. van ‘t Veer is the 2024 recipient of the William L. McGuire Memorial Lecture Award. She was recognized for her…

Andrew Tutt, MB, ChB, PhD, director of the breast cancer research teams at The Institute of Cancer Research in London, talks with Julie Nangia, MD, about the results of the phase 3 OlympiA trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1 and BRCA2 pathogenic variants and high-risk HER2-negative primary breast cancer.

Matteo Lambertini, MD, PhD, associate professor at the University of Genova – IRCCS, talks with Marcela Mazo Canola, MD, about the association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer.

Jennifer A. Ligibel, MD, senior physician in the Breast Oncology Center at Dana-Farber Cancer Institute, Boston, Massachusetts, talks with Lindsay L. Peterson, MD, MSCR, about results from the Breast Cancer Weight Loss (BWEL) Trial, which tested the efficacy of a weight loss intervention on metabolic and inflammatory biomarkers in women with obesity and breast cancer.